bluetongue
MONDO:0025385
A reovirus infection, chiefly of sheep, characterized by a swollen blue tongue, catarrhal inflammation of upper respiratory and gastrointestinal tracts, and often by inflammation of sensitive laminae of the feet and coronet.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Bluetongue disease
Bluetongue (BT) disease is a noncontagious, arthropod-borne viral disease affecting ruminants, primarily sheep and other domestic or wild ruminants, including cattle, yaks, goats, buffalo, deer, dromedaries, and antelope. It is caused by bluetongue virus (BTV), a nonenveloped, double-stranded RNA virus belonging to the genus Orbivirus within the family Sedoreoviridae. The virus is mainly transmitted by biting midges, specifically Culicoides species (e.g. Culicoides imicola, C. oxystoma, and C. variipennis). BTV has a widespread geographical distribution, encompassing numerous continents and regions, including Africa, Asia, Australia, Europe, North America, and various tropical and subtropical regions. At present, there are more than 28 recognized serotypes of BTV. Bluetongue outbreaks have had a significant economic impact, with estimated annual global losses reaching around US$3 billion.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.